옵션 체인은 다양한 행사가격과 만기일에 대한 Cabaletta Bio의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Cabaletta Bio에 대한 시장 심리를 평가합니다..

Cabaletta Bio (NASDAQ:CABA) 주식, 옵션 체인

CABALETTA BIO INC

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Prescription Drugs

Equities

Markets

CABA

카발레타 바이오(NASDAQ:CABA)의 주가는 수요일 24.38% 상승한 3.01달러에 마감했으며, 전신 경화증(Systemic Sclerosis) 약물 시험 업데이트 이후 시간외 거래에서 4.65% 상승한 주당 3.15달러에 거래되었다.

카발레타 바이오, 전신 경화증 약물 시험 업데이트 이후 수요일 23개월 만에 최대 급등

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

Business&nbsp;Combination&nbsp;Would Unlock&nbsp;Significant&nbsp;Value&nbsp;for&nbsp;Cartiga as&nbsp;a Nasdaq-Listed Tech-Forward Vertically-Integrated Alternative Asset Management Company
NEW YORK, May 12, 2025 /PRNewswire/ -- Alchemy Investments Acquisition Corp 1 ("Alchemy"( (Nasdaq: <a href="https://www.benzinga.com/stock/alcy#Nasdaq">ALCY</a>), a publicly traded special purpose acquisition company ("SPAC"), has entered into a non-binding letter of intent with Cartiga, LLC, a Delaware limited liability company ("Cartiga" and together with Alchemy, the "Parties"), in connection with a potential business combination ("Business Combination").

News

ALCY

Alchemy Investments Signs Non-Binding LOI For Potential Business Combination with Cartiga

WIIM

Hudbay Minerals shares are trading higher after the company reported better-than-expected Q1 financial results.

AAPL: 7% &#x7C; <a href="https://www.benzinga.com//node/45342755">The Wall Street Journal Reported Apple Is Weighing Fall iPhone Price Increases; Won't Attribute Hikes to Tariffs</a>
&nbsp;
KDLY: 590% &#x7C; <a href="https://www.benzinga.com//node/45343940">KindlyMD Enters InTo Definitive Merger Agreement With Nakamoto Holdings To Establish Bitcoin Treasury; Raises $510M PIPE and $200M In Convertible Notes</a>
&nbsp;
&nbsp;

Movers

Trading Ideas

AAPL

KDLY

Market-Moving News for May 12th

Canaccord Genuity analyst Austin Moeller maintains Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) with a Buy and lowers the price target from $18 to $17.5.

Price Target

Analyst Ratings

CBUS

Canaccord Genuity Maintains Buy on Cibus, Lowers Price Target to $17.5

UroShield Demonstrates Significant Reductions in CAUTIs, Catheter Blockages and Hospital Visits
NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) (the "Company"), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield&#x2122; system.
The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield device for durations ranging from 12 weeks to 17 months. The series reviewed pre- and post-treatment data on catheter-associated urinary tract infections (CAUTIs), catheter blockages, unplanned hospital visits and patient satisfaction.

NAOV

NanoVibronix: UroShield Shows Reductions In CAUTIs, Catheter Blockages And Hospital Visits

Shiseido Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSDOY#OTC">SSDOY</a>) reported quarterly earnings of $0.06 per share. This is a 200 percent increase over losses of $(0.06) per share from the same period last year. The company reported $1.50 billion in sales this quarter. This is a 10.95 percent decrease over sales of $1.68 billion the same period last year.

Earnings

SSDOY

Shiseido Co Q1 EPS $0.06 Up From $(0.06) YoY, Sales $1.50B Down From $1.68B YoY

Wayfair shares are trading higher after Argus Research upgraded the stock from Hold to Buy and announced a $40 price target.

BHP Group shares are trading higher after a judge blocked an Arizona land transfer to Rio Tinto.

CSX shares are trading higher after the company announced it reached a labor agreement with the Brotherhood of Locomotive Engineers and Trainmen on a new 5-year single-system covering approximately 3,400 engineers.

Alchemy Investments Acquisition Corp 1 Shares Halted, News Pending

Suzuki Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SZKMY#OTC">SZKMY</a>) reported quarterly earnings of $1.42 per share. This is a 408.7 percent increase over losses of $(0.46) per share from the same period last year. The company reported $10.11 billion in sales this quarter. This is a 1.77 percent decrease over sales of $10.29 billion the same period last year.

SZKMY

Suzuki Motor Q4 EPS $1.42 Up From $(0.46) YoY, Sales $10.11B Down From $10.29B YoY

Somnigroup shares are trading higher amid overall market strength after the US and China agreed to temporarily suspend most tariffs. The company initially dipped after it announced a secondary offering.

ALCYU

Trading Halt: Halted at 8:46:30 a.m. ET - Trading Halt: Halt News Pending

ALCYW

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) ("Omeros" or the "Company") today announced that it has entered into exchange agreements (the "Exchange Agreements") with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the "2026 Convertible Notes") to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion rate set at a 35% premium as described below (the "New Convertible Notes"). The exchange, which extends the maturity of a significant portion of the Company's outstanding indebtedness, is expected to close on or about May 14, 2025.
In addition, Omeros today announced that it has entered into an agreement (the "Note Conversion Agreement") with an investor to convert $10 million aggregate principal amount of 2026 Convertible Notes into shares of the Company's common stock, par value $0.01 per share (the "Equitization Transaction").
Following the completion of these transactions, approximately $17.4 million aggregate principal amount of the 2026 Convertible Notes will remain outstanding. This reduction in principal balance of the 2026 Convertible Notes outstanding will prevent the Company from being required to make a $20.0 million prepayment of the term loan outstanding under its 2024 Credit and Guaranty Agreement. This prepayment otherwise would have become due in November 2025. As a result of these transactions, the Company expects that its outstanding debt will be reduced by $10.0 million and its potential debt repayment obligations over the next 12 months will be reduced from $117.9 million to approximately $17.4 million.

OMER

Omeros Agrees To Acquire $80.5M Of Its Convertible Senior Notes Due 2026

NRXS

CORRECTION: Neuraxis Q1 EPS $(0.33) Down From $(0.32) YoY, Sales $895.65K Up From $646.63K YoY

Major cryptocurrencies are holding firm on Monday morning as investor sentiment improves on news of a <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45344686/can-the-us-china-tariff-de-escalation-send-bitcoin-ethereum-to-new-highs">U.S.-China tariff pause. </a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$103,945.97</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,550.52</td>
<td>+1.2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$175.02</td>
<td>+0.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.53</td>
<td>+6.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2437</td>
<td>+4.4%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001679</td>
<td>+4.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin large transaction volume grew 3%, while daily active addresses dropped 7.4% in a single day.</li>
<li>Coinglass data shows 147,351 traders were liquidated in the past 24 hours for $392.16 million.</li>
<li>Discord groups flagged a sharp rise in Bitcoin open interest, with $1.7 billion added in a day, noting that longs are pushing the price action upward despite rising funding rates.</li>
</ul>
Trader Notes: Nic Puckrin, founder and investor of Coin Bureau, says Bitcoin's rally reflects improving risk appetite as tariff reduction talks between the U.S. and China lower geopolitical friction. 
Gold has dropped over 3%, reinforcing a rotation away from safe-haven assets.
"Bitcoin has shifted back to a risk-on asset," Puckrin noted. "It's once again trading in step with equities and could soon break its all-time high."
However, he cautioned that the altcoin rally lacks staying power without significant retail engagement. 
Despite ETF-driven hype, the absence of mainstream inflows could limit upside for most non-BTC assets.
McKenna <a href="https://x.com/Crypto_McKenna/status/1921830409601794289">says</a> Bitcoin's one-day mean reversion signals will activate above $110,000, suggesting consolidation may follow. Still, he's confident that with liquidity tailwinds, new all-time highs are a matter of "when," not "if."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin continues its march to the upper range of the linear reg channel. 1D mean reversions to the upside begin to flash when BTC is above $110k so getting close. Think Bitcoin will enter a period of consolidation here. But I am in the view new all time highs in 2025 are… <a href="https://t.co/E1Dc5id4z2">pic.twitter.com/E1Dc5id4z2</a>
&mdash; McKenna (@Crypto_McKenna) <a href="https://twitter.com/Crypto_McKenna/status/1921830409601794289?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, CW <a href="https://x.com/CW8900/status/1921801797938630687">reports</a> that Solana has cleared its sell wall, with no resistance until $270. Trader Tardigrade is <a href="https://x.com/TATrader_Alan/status/1921870983121818012">calling</a> for a parabolic Dogecoin surge, pointing to signs of accelerated accumulation.
Chris Burniske, former ARK Invest executive, <a href="https://x.com/cburniske/status/1921858460003467451">says</a> he's long Ethereum, expecting both ETH and BTC to outperform this cycle. Ted Pillows <a href="https://x.com/TedPillows/status/1921893104493166859">adds</a> that Ethereum is holding its breakout and could rally soon if momentum continues.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45344022/bitcoin-taps-105000-heres-when-it-could-hit-122000">Bitcoin Taps $105,000: Here&#8217;s When It Could Hit $122,000</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Gains As US, China Agree To Lower Tariffs

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested
Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin for the treatment of R/R AML; Interim data readout expected in the second half of 2025
Subjects targeted for the "MIRACLE" trial include venetoclax regimen failures where outcomes with currently available therapies are considered dismal
HOUSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) to conduct its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC"). The study is for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML) and is approved in all nine countries submitted in the European Union (EU). This Phase 3 "MIRACLE" trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East.

MBRX

Moleculin Biotech Receives EMA Approval For Clinical Trial Application To Conduct Pivotal Phase 2B/3 AnnAraC Clinical Trial

Economist Craig Shapiro shared his insights on the unfolding U.S.-China trade dynamics, warning that while a tariff truce may calm immediate market fears, it could have unintended consequences for the broader economy.
What Happened: Shapiro, a macro strategist at Bear Traps Report, suggested that the so-called &#8220;tariff climb down&#8221; might prevent bond yields from falling, thereby maintaining pressure on an already strained economy as the Federal Reserve remains on the sidelines.
Shapiro's analysis, posted on X, builds on his earlier reflections from May 9, where he drew parallels to the 2018 Donald Trump, Xi Jinping G20 summit in Argentina. Back then, a temporary trade truce sparked market euphoria, driving a brief rally as volatility subsided.
However, the optimism was short-lived. Markets tanked in the following weeks as the reality of implementing a deal set in, compounded by a slowing economy and a Federal Reserve that was tightening policy through quantitative tightening.
The situation only stabilized after the former Treasury Secretary Steven Mnuchin's emergency Christmas Eve call to major banks and Fed Chair Jerome Powell's subsequent policy pivot in early 2019.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sticking with this call Tariff Climb down will alleviate the worst fears but the reality is that the cave will make it hard for yields to fall which keeps the economy under pressure as the Fed sits on its hands. <a href="https://t.co/BdWKBOUf8o">https://t.co/BdWKBOUf8o</a>
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1921845051589640249?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His comments come amid a backdrop of heightened trade tensions, with recent reports indicating that President Trump paused reciprocal tariffs for 90 days, leaving a baseline 10% rate in place. Despite this reprieve, bond yields have remained stubbornly high.
The 10-year Treasury yields jumped to 4.45% as of the publication of this article.
Thus, according to Shapiro, inflationary effects could continue to push up prices and inflation expectations, and this will prevent bond yields from falling, as investors demand higher yields to offset inflation risk and perceived economic uncertainty.
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs</a>
Why It Matters: On Monday, the U.S. and China declared a <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">90-day suspension</a> of reciprocal tariffs, reducing them from 125% to 10%, following notable progress in<a href="https://www.benzinga.com/news/global/25/05/45337811/trump-announces-total-reset-as-us-china-trade-talks-aim-to-end-tariff-war"> trade discussions</a> held in Geneva over the weekend, as indicated by both the White House and Chinese officials. 
The U.S. will keep its 20% tariffs on Chinese imports related to fentanyl, resulting in a total tariff rate on China of 30%. Treasury Secretary Scott Bessent commented, &#8220;We had very productive talks and I believe that the venue, here in Lake Geneva, added great equanimity to what was a very positive process."
According <a href="https://www.scmp.com/economy/global-economy/article/3309975/china-us-reduce-majority-tariffs-after-first-round-trade-talks?module=top_story&amp;pgtype=homepage">to</a> the South China Morning Post, the joint U.S.-China statement also revealed that Beijing has agreed to lift or suspend all non-tariff countermeasures in place since April 2, which include export restrictions on critical minerals and sanctions on certain U.S. companies. 
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Monday. The SPY was up 3.04% to $581.50, while the QQQ advanced 3.90% to $507.02, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Friday, the SPY was down 0.13% to $564.34, while the QQQ declined 0.066% to $487.97
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45344120/cathie-wood-says-ai-innovation-in-healthcare-will-be-more-profound-than-autonomous-taxi-ne">Cathie Wood Says AI Innovation In Healthcare Will Be More &#8216;Profound&#8217; Than Autonomous Taxi Networks, Humanoid Robots</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Analyst Color

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

ETFs

General

US-China Tariff Truce Will Alleviate 'Worst Fears,' But Prevent Falling Yields, Keeping 'Economy Under Pressure,' Says Craig Shapiro

Press Releases

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Health Care

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Comments

Cabaletta Bio

Cabaletta Bio (CABA) 옵션

Cabaletta Bio (NASDAQ:CABA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌